About ArsenalBio
Arsenal Biosciences, Inc. (ArsenalBio) is a clinical-stage programmable cell therapy company headquartered in South San Francisco, CA, focused on engineering advanced CAR T-cell therapies for solid tumors. Their full-stack R&D engine uses CRISPR-mediated genome editing, synthetic biology integrated circuits with logic gating, and a computationally driven approach to develop next-generation autologous T cell therapies. The company's pipeline targets cancers including kidney, ovarian, and prostate, with lead candidates co-developed in partnership with Bristol-Myers Squibb and Roche.
Company details
Funding
Total raised
$603.3M
Last stage
Growth
Investors
Founders
Kole Roybal
Scientific co-founder; Assistant Professor of Immunology at UCSF and PICI Investigator; contributed synthetic biology and cell engineering expertise to ArsenalBio's founding platform.
Ken Drazan
MD; previously President & Chief Business Officer of GRAIL (acquired by Illumina); founder and Board Director of Verb Surgical (acquired by J&J); co-founded private equity firm Bertram Capital; board-certified liver transplant surgeon with prior faculty appointments at Stanford and UCLA.
LinkedInW. Nicholas Haining
Physician-scientist; formerly VP of Discovery Oncology and Immunology at Merck Research Laboratories; Associate Professor of Pediatrics at Harvard Medical School; Associate Member of the Broad Institute of Harvard and MIT.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.